marketcaparena

Virax Biolabs Group Ltd

VRAX

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

viraxbiolabs.com ↗

Leadership

  • James Alexander Cunliffe FosterChief Executive Officer
  • Jason DavisChief Financial Officer
  • Nigel William McCrackenChief Operating Officer
Employees
26
Business address
LANARKSHIRE, X0
Fiscal year ends
March 31
Listed
Nasdaq · VRAX

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$2.31
−$13.01 (−84.90%)past year
Market cap
$54K
At close
Sep 28, 2026

Share price vs index

Virax Biolabs Group's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Virax Biolabs Group is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY26
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY26
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Operating leverage

FY26
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY26
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY26
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY26
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY26
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 26
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 26
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.